Kevin Kunzmann

In 2015, a study changed the entire understanding of peanut allergen exposure. Physicians are still trying to understand how to implement it today.

A new cohort analysis shows hospitalized smokers are not at complication risk due to the perioperative therapy.

An international, 5000-patient cohort shows a majority of patients are white, female, and non-smokers.

Are current methods and biomarkers viable, or are there better options to uncover?

How findings from AHA show early ANGPTL3 and APOC3 benefits in cardiometabolic health, via liver protein targeting.

How women's health burdens touch genetics, psychiatry, cardiology, and whether physicians are equipped to manage it all.

In months, the US may have its first marketed peanut immunotherapies. How will pediatric patient management change?

An analysis of mepolizumab use shows fewer than 1% of prescribed patients are likely to use biologics concomitantly.

Toujeo has been given an added indication which allows its use for blood sugar control in patients as young as 6 years old.

The deoxygenated sickle hemoglobin polymerization inhibitor was granted Accelerated Approval designation for the burdensome rare disease.

Patient demographics influence difference symptoms, progression, and benefits of care.

How to weigh the 5 agents from the drug class, which have each shown differing benefit in younger patients.

Though vaccination rates are decreasing in children and adolescents overall, it is not due to consideration of previous season's successes or failures.

The once-daily oral therapy is recommended at a 200 mg dose, following titration.

Why US patients are now in absolute need of proven measures to lessen their risk of cardiovascular burden.

What more needs to be learned about the link between the 2 diseases?

The new trial will seek to understand whether atrial fibrillation screening reduces stroke risk.

The therapy was shown in a 94-patient trial to reduce porphyria attacks by 70% versus placebo.

The study author provides insight into the benefit of inclisiran in at-risk patients with ASCVD.

How preventive care strategy adherence could bolster heart disease risk reduction in entire families.

The understood risk of cancer development in patients with cardiovascular disease requires improved care teams.

A look into the findings of ticagrelor in high risk patients, with or without aspirin.

Promising drug inclisiran shows significant LDL cholesterol reduction in patients with familial hypercholesterolemia.

How cardiologists have forged the often different goals of improving patients' life expectancies, with improving their quality of life.

A new study from UT Southwestern shows a new indicator of patient fringe risk for high blood pressure.

A national study underlined a persistent trend of cardiovascular events among US women near giving birth.

New findings from ESCaPE-MD show CD34+ cell therapy significantly benefitted patients with coronary microvascular dysfunction over 6 months.

New empagliflozin data assesses the SGLT-2 inhibitor versus GLP-1 agonists and DPP-4 inhibitors for patients with heart failure.

The adult heart failure study is the first of its kind: a completely decentralized, indication-seeking clinical trial.

Results from the 400,000-plus patient trial show a pulse detection app on the Apple Watch may aid users in detecting risks of atrial fibrillation.